Targeting multiple angiogenic pathways for the treatment of neuroblastoma

Journal of Pediatric Surgery

Volumn 45, Issue 6, 2010, Pages 1103-1109

  Williams, Regan F ^a,b   Myers, Adrianne L ^a,b   Sims, Thomas L ^a,b   Ng, Catherine Y ^a   Nathwani, Amit C ^c   Davidoff, Andrew M ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Angiogenesis; Interferon ; Neuroblastoma; Rapamycin

Indexed keywords

BETA INTERFERON; PARVOVIRUS VECTOR; RAPAMYCIN; ACTIN; ANTINEOPLASTIC ANTIBIOTIC; CD34 ANTIGEN; IMMUNOLOGIC FACTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER; MALE; MONOTHERAPY; MOUSE; NEUROBLASTOMA; NONHUMAN; PERICYTE; PHENOTYPE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; ANIMAL; CLUSTER ANALYSIS; COMPARATIVE STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; RETROPERITONEAL NEOPLASMS; SCID MOUSE; TUMOR CELL CULTURE; VASCULARIZATION; XENOGRAFT;

ACTINS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD34; CLUSTER ANALYSIS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC FACTORS; INJECTIONS, INTRAPERITONEAL; INTERFERON-BETA; MALE; MICE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; RETROPERITONEAL NEOPLASMS; SIROLIMUS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 77953851272     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpedsurg.2010.02.073     Document Type: Article

References (21)

1. Maris J.M., Hogarty M.D., Bagatell R., et al. Neuroblastoma. Lancet 369 (2007) 2106-2120
2. Risau W. Mechanisms of angiogenesis. Nature 386 (1997) 671-674
3. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29 (2002) 15-18
4. Kerbel R., and Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev 2 (2002) 727-739
5. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
6. Borden E.C. Interferons and cancer: where from here?. J Interferon Cytokine Res 25 (2005) 511-527
7. Dickson P.V., Hamner J.B., Streck C.J., et al. Continuous delivery of IFN-beta promotes sustained maturation of intratumoral vasculature. Mol Cancer Res 5 6 (2007) 531-542
8. Guertin D.A., and Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 12 (2007) 9-22
9. Johnsen J.I., Segerstro L., Orrego A., et al. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 27 20 (2008) 2910-2922
10. Murphy J.D., Spalding A.C., Somnay Y.R., et al. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature. Clin Cancer Res 15 (2009) 589-596
11. Streck C.J., Zhang Y., Miyamoto R., et al. Restriction of neuroblastoma angiogenesis and growth by interferon-alpha/beta. Surgery 136 (2004) 183-189
12. Davidoff A.M., Ng C.Y., Zhou J., et al. Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood 102 (2003) 480-488
13. Davidoff A.M., Ng C.Y., Sleep S., et al. Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock. J Virol Methods 121 (2004) 209-215
14. Spurbeck W.W., Ng C.Y., Strom T.S., et al. Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model. Blood 100 (2002) 3361-3368
15. Dickson P.V., Hamner J.B., Sims T.L., et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13 (2007) 3942-3950
16. Kerbel R.S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessay 13 (1991) 31-36
17. Zhang L., Smith K.M., Chong A.L., et al. In vivo antitumor and antimetastatic activity of Sunitinib in a preclinical neuroblastoma mouse model. Neoplasia 11 (2009) 426-435
18. Marimpietri D., Brignole C., Nico B., et al. Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis. Clin Cancer Res 13 (2007) 3977
19. Marimpietri D., Nico B., Vacca A., et al. Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin. Oncogene 24 (2005) 6785-6795
20. Streck S.J., Ng C.Y., Zhanga Y., et al. Interferon-mediated anti-angiogenic therapy for neuroblastoma. Cancer Lett 228 (2005) 163-170
21. Dickson P.V., Hagedorn N.L., Hamner J.B., et al. Interferon beta-mediated vessel stabilization improves delivery and efficacy of systemically administered topotecan in a murine neuroblastoma model. J Pediatr Surg 42 (2007) 160-165